Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Fort Lauderdale, Florida Clear all
Recruiting Phase 2Phase 3 Interventional

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

NCT07440225
View directory record Official record
Conditions
Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Interventions
Tiespectus, Aflibercept
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
50 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
67
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Springdale, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Recruiting Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

NCT06024746
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone, Empagliflozin
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Fairhope, Alabama • Phoenix, Arizona • Chula Vista, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT06972472
View directory record Official record
Conditions
Obesity, Overweight, Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Sun City West, Arizona • Tucson, Arizona • San Ramon, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

NCT04506905
View directory record Official record
Conditions
Schizophrenia
Interventions
Elpipodect, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
6
States / cities
Rogers, Arkansas • Glendale, California • Long Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

NCT00071331
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
161
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 21, 2026, 10:17 AM EDT
Active, not recruiting Phase 3 Interventional

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183
View directory record Official record
Conditions
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
68
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Fountain Valley, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

NCT03677934
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
77
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

NCT00057356
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
conivaptan, placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
26
States / cities
Huntsville, Alabama • Los Angeles, California • Manteca, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain

NCT02367820
View directory record Official record
Conditions
Low Back Pain, Chronic Pain
Interventions
NKTR-181 BID tablets
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
56
States / cities
Saraland, Alabama • Phoenix, Arizona • Tempe, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

NCT01489189
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation
Other · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
48
States / cities
Phoenix, Arizona • Loma Linda, California • Palm Springs, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

NCT04423718
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

NCT04820309
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
116
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

NCT04566666
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
Placebo, SCD-044_Low Dose (Dose 1), SCD-044_Intermediate Dose (Dose 2), SCD-044_High Dose (Dose 3)
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Yuma, Arizona • Encino, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03412890
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
104
States / cities
Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

Anti-VEGF Treatment for Prevention of PDR/DME

NCT02634333
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

NCT05182840
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
41
States / cities
Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 21, 2026, 10:17 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

NCT05224102
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Arcadia, California • Campbell, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT04777201
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Faricimab, Sham Procedure, Anti-VEGF Therapy
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
1,036 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
85
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT04592419
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
81
States / cities
Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 21, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

NCT04503551
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Recruiting No phase listed Observational

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

NCT03072927
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
MILD, Interspinous Process Decompression
Device
Lead sponsor
Stryker Instruments
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2383
States / cities
Athens, Alabama • Bay Minette, Alabama • Birmingham, Alabama + 1285 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06957080
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Remigromig, Ranibizumab
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
107
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Active, not recruiting Phase 3 Interventional

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 21, 2026, 10:17 AM EDT
Terminated Phase 1 Interventional Results available

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

NCT05384119
View directory record Official record
Conditions
Breast Cancer
Interventions
TTI-101, Palbociclib, Aromatase inhibitor (AI), fulvestrant, ribociclib
Drug
Lead sponsor
Tvardi Therapeutics, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Fort Lauderdale, Florida • St Louis, Missouri • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 10:17 AM EDT